Literature DB >> 6107946

Differential behavioral and biochemical effects of four dopaminergic agonists.

G Gianutsos, K E Moore.   

Abstract

Some behavioral and biochemical effects of four dopaminergic agonists (apomorphine, piribedil, lergotrile, and bromocriptine) were determined in the mouse. As expected, all four drugs dose-dependently reversed the alpha-methyltyrosine-induced decline of forebrain dopamine. All four compounds reduced locomotor activity at low doses, but only apomorphine and bromocriptine increased motor activity at higher doses. All four drugs caused some reversal of the baclofen-induced elevation in forebrain dopamine concentrations, but only apomorphine and bromocriptine completely reversed the effects of baclofen. After chronic treatment with haloperidol, the behavioral effects of lergotrile and bromocriptine were altered. Doses of those drugs reducing motor activity in normal animals were ineffective after chronic haloperidol. The latent stimulation induced by bromocriptine was enhanced, while a stimulatory effect of lergotrile emerged in these animals. These effects were noted in conjunction with an enhanced sensitivity to the drug-induced decrease in dopamine turnover. These results demonstrate that dopamine agonists may be differentiated on the basis of certain behavioral and biochemical tests and suggest an interaction of these drugs with two different populations of dopamine receptors.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6107946     DOI: 10.1007/bf00432131

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  34 in total

1.  A SENSITIVE METHOD FOR SPECTROPHOTOFLUOROMETRIC ASSAY OF CATECHOLAMINES.

Authors:  C C CHANG
Journal:  Int J Neuropharmacol       Date:  1964-12

2.  Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data.

Authors:  A R Cools; J M Van Rossum
Journal:  Psychopharmacologia       Date:  1976-02-02

3.  Similarities and differences of dopamine receptors in the renal vascular bed and elsewhere.

Authors:  L I Goldberg; P H Volkman; J D Kohli; A N Kotake
Journal:  Adv Biochem Psychopharmacol       Date:  1977

4.  Bromocriptine, dihydroergotoxine, methysergide, d-LSD, CF25--397, and 29--712: effects on the metabolism of the biogenic amines in the brain of the rat.

Authors:  H R Bürki; H Asper; W Ruch; P E Züger
Journal:  Psychopharmacology (Berl)       Date:  1978-05-31       Impact factor: 4.530

5.  Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.

Authors:  M Goldstein; A Lieberman; A F Battista; J Y Lew; F Hata
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

6.  ET495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors.

Authors:  H Corrodi; L O Farnebo; K Fuxe; B Hamberger; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1972-11       Impact factor: 4.432

7.  Dopamine concentrations in the rat brain following injections into the substantia nigra of baclofen, gamma-aminobutyric acid, gamma-hydroxybutyric acid, apomorphine and amphetamine.

Authors:  P H Kelly; K E Moore
Journal:  Neuropharmacology       Date:  1978-03       Impact factor: 5.250

8.  Differential actions of dopamine agonists and antagonists on the gamma-butyrolactone-induced in mouse brain dopamine.

Authors:  G Gianutsos; J E Thornburg; K E Moore
Journal:  Psychopharmacology (Berl)       Date:  1976-11-24       Impact factor: 4.530

9.  Effect of lergotrile on 3,4-dihydroxyphenylacetic acid (DOPAC) concentration and dopamine turnover in rat brain.

Authors:  R W Fuller; K W Perry
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

10.  Tolerance to the effects of baclofen and gamma-butyrolactone on locomotor activity and dopaminergic neurons in the mouse.

Authors:  G Gianutsos; K E Moore
Journal:  J Pharmacol Exp Ther       Date:  1978-12       Impact factor: 4.030

View more
  9 in total

1.  Amphetamine, apomorphine and investigatory behavior in the rat: analysis of the structure and pattern of responses.

Authors:  A E Kelley; M Winnock; L Stinus
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Pharmacological characterization of the receptors involved in the apomorphine-induced polyphasic modifications of locomotor activity in mice.

Authors:  P Protais; J J Bonnet; J Costentin
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

3.  Differentiation of apomorphine from bromocriptine, piribidel and TRH by chronic administration in rats.

Authors:  F Porreca; A Cowan; R J Tallarida
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

4.  Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine.

Authors:  M R Zarrindast; M Poursoltan
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

5.  Role of dopamine receptors in the regulation of aggression in mice; relationship to genotype.

Authors:  E M Nikulina; N S Kapralova
Journal:  Neurosci Behav Physiol       Date:  1992 Sep-Oct

6.  Effects of three dopamine agonists on cage climbing behavior.

Authors:  G Gianutsos; J L Palmeri
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

7.  Production of climbing behaviour in mice requires both D1 and D2 receptor activation.

Authors:  N A Moore; M S Axton
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Differential action of bromocriptine on nigrostriatal versus mesolimbic dopaminergic neurons.

Authors:  A C Barton; K E Moore; K T Demarest
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

9.  Involvement of septal and striatal dopamine D-2 receptors in yawning behavior in rats.

Authors:  K Yamada; M Tanaka; K Shibata; T Furukawa
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.